The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial
Open accessAbstract
Background: Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited. Methods: This was a randomized, multicenter, open-label, noninferiority trial. Inpatients with gram-negative bacteremia, who were afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 days (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative, or distant complications; and readmission or extended hospitalization (>14 days). The noninferiority margin was set at 10%. Results: We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in 3 centers in Israel and Italy. The source of the infection was urinary in 411 of 604 patients (68%); causative pathogens were mainly Enterobacteriaceae (543/604 [90%]). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140 of 306 patients (45.8%) in the 7-day group vs 144 of 298 (48.3%) in the 14-day group (risk difference, –2.6% [95% confidence interval, –10.5% to 5.3%]). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short-course therapy arm. Conclusions: In patients hospitalized with gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was noninferior to 14 days. Reducing antibiotic treatment for uncomplicated gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention. Clinical Trials Registration: NCT01737320.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Biomarker-guided strategies, randomized trials of bloodstream infection duration, and recent meta-analyses have shown that less antibiotic exposure can be appropriate in selected patients when clinical stability and source control are present (24–29).”
From Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis (2026) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“More recently, SARS-CoV-2 (causing COVID-19) is now responsible for many cases of infection and sepsis (223).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [223]
Experimental — accuracy not yet measuredIn the citing paper
“In many of the trials, the shorter course was just as effective as the longer course but associated with fewer adverse consequences.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [292]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,045
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Trial of short-course antimicrobial therapy for intraabdominal infection.
Sawyer, R. G., Claridge, J. A., Nathens, A. B., Rotstein, O. D., Duane, T. M., Evans, H. L., Cook, C. H., O’Neill, P. J., Mazuski, J. E., Askari, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411162 · Cited by 747
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Evans, S. R., Rubin, D., Follmann, D. A., Pennello, G. A., Huskins, W. C., Powers, J. H., Schoenfeld, D., Chuang‐Stein, C., Cosgrove, S. E., Fowler, V. G., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ495 · Cited by 363
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Havey, T. C., Fowler, R. A., & Daneman, N. (2011) · Critical Care · doi:10.1186/cc10545 · Cited by 187
Chotiprasitsakul, D., Han, J., Cosgrove, S. E., Harris, A. D., Lautenbach, E., Conley, A. T., Tolomeo, P., Wise, J. A., Tamma, P. D., & Antibacterial Resistance Leadership Group (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix767 · Cited by 173
Eliakim-Raz, N., Yahav, D., Paul, M., & Leibovici, L. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt177 · Cited by 153
Self-citationStrategies for Reduction in Duration of Antibiotic Use in Hospitalized Patients
Hayashi, Y., & Paterson, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir063 · Cited by 138
Royer, S., DeMerle, K. M., Dickson, R. P., & Prescott, H. C. (2018) · Journal of Hospital Medicine · doi:10.12788/jhm.2905 · Cited by 94
Long-term consequences of severe infections
Leibovici, L. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12160 · Cited by 72
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- US Food and Drug Administration, Center for Drug Evaluation and Research., Complicated urinary tract infections: developing drugs for treatment guidance for industry. Available at:
Cited by
Sorted by citations
Items 401–432 of 432
de Jong, E. P., Chang, C.-Y., Chen, C.-H. S., Lin, W.-C., & Chan, C. C. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003448
Tate, T., Smith, B. J., Viehman, J. A., & Shields, R. K. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag120
Hojat, L., & Spivak, E. S. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag145
Antibiotic Stewardship for the Intensivist
Hawes, A. M., & Cosgrove, S. E. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.01.004
Variceal hemorrhage in cirrhosis
Chara, B. S., & García–Tsao, G. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2656231
Zheng, S., Yang, L., Shi, C., Xu, C., & Li, T. (2026) · Antibiotics · doi:10.3390/antibiotics15050476
Jahan, E., Matika, A., Allen, L., & Miller, J. (2026) · Infection · doi:10.1007/s15010-026-02898-5
Zuccaro, V., Asperges, E., Marvulli, L. N., Valsecchi, P., Pagani, E., Sacchi, P., & Bruno, R. (2026) · Infection · doi:10.1007/s15010-026-02821-y
Fronrath, M., Martz, C. R., Griebe, K. M., Veve, M. P., & Smith, Z. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124768
Mazzitelli, M., Serraino, R., Trecarichi, E. M., Murri, R., & Torti, C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2692475
Barrio, M. S., Schüffelmann, C., Vico, A. D., & Vergara, E. O. (2026) · Medicina Intensiva · doi:10.1016/j.medin.2026.502543 · Cited by 1
Forestier, E., Soudais, B., Caspar, Y., Etienne, M., Milacic, H., Orcel, V., Baudron, C. R., Vallée, M., Dinh, A., & Lafaurie, M. (2026) · Infectious Diseases Now · doi:10.1016/j.idnow.2026.105319
Jones, J., Colven, R. B., Morrisette, T., Hornback, K. M., Deloney, L. P., Gruss, Z. P., Alvira-Arill, G. R., Delay, T. A., & Hamby, A. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10771
Kumar, R. N. (2026) · Current Infectious Disease Reports · doi:10.1007/s11908-026-00889-z
Inappropriate antibiotic duration in common infections: Are we treating habits rather than evidence?
Patel, A. B. (2026) · RMC Global Journal · doi:10.25259/rmcgj_54_2025
Rodríguez-Urbistondo, C., & Cisneros, J. M. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107537
Zohar, I., Melloul, D., Satra-Shenes, B., Schwartz, O., David, D. B., & Maor, . (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05613-2
Hashimoto, T., Sagami, R., Hiroshima, Y., Yoshikawa, H., Komiya, K., & Hiramatsu, K. (2026) · IDCases · doi:10.1016/j.idcr.2026.e02720
Botill, B., Bui, L., Collins, J., Hearing, A., & Guirguis, E. H. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.198
Byskov, E. S., Pereira, L. G., Pirolo, M., Pedersen, K. S., Olsen, J. E., Guardabassi, L., & Damborg, P. (2026) · Porcine Health Management · doi:10.1186/s40813-026-00534-0
Shinohara, K., Tochitani, K., Katada, Y., Murata, T., Morita, M., Tsuda, Y., Tsuchido, Y., Yamamoto, M., Matsumura, Y., & Nagao, M. (2026) · Infection · doi:10.1007/s15010-026-02938-0
Owchithya, D. D., Sridhar, P. D. J., Dhinesh Kumar, M., Dr Premnath, R., & Dr. Karthik Shivanesh, S. (2026) · PAIN JOINTS SPINE · doi:10.1922/pjs.16.5s.2026.761
Optimising the duration of antimicrobial treatment in the era of Antimicrobial Stewardship Programs
Rodríguez-Urbistondo, C., & Cisneros, J. M. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2026.107537
Barrio, M. S., Schüffelmann, C., Vico, A. D., & Vergara, E. O. (2026) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2026.502543
Kim, D., Wright, E., & Moretti, L. (2024) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/qokj1cthtt
Roganović, J., & Roganović, V. (2026) · Antibiotics · doi:10.3390/antibiotics15090924
Dittmar, C. M., Coughlin, A., O’Neal, M., Piccicacco, N., & Zeitler, K. E. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10881
Early versus late transition to oral antibiotics in Enterobacterales bacteremia
Yahia, M., Falk, C. L., Yost, R. J., & Geyer, A. C. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10886
Naegele, S., Baik, B., Ravichandran, U., Shah, N. S., & Acree, M. E. (2026) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2026.10892
Shorter Antibiotic Duration for Pseudomonas Bacteremia: A Call for Future Trials
Albuquerque, A. M., Santolia, C. B., Zampieri, F. G., Brophy, J. M., & Lee, T. C. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag646
Pascale, R., Montironi, M., & Giannella, M. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001242
Metadata
- Authors
- Yahav, D., Franceschini, E., Koppel, F., Turjeman, A., Babich, T., Bitterman, R., Neuberger, A., Ghanem-Zoubi, N., Santoro, A., Eliakim-Raz, N., Pertzov, B., Steinmetz, T., Stern, A., Dickstein, Y., Maroun, E., Zayyad, H., Bishara, J., Alon, D., Edel, Y., Goldberg, E., Venturelli, C., Mussini, C., Leibovici, L., Paul, M., & Bacteremia Duration Study Group
- Affiliations
- Tel Aviv University (IL)
- University of Modena and Reggio Emilia (IT)
- Rambam Health Care Campus (IL)
- Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
- Technion – Israel Institute of Technology (IL)
- Infectious Diseases Institute, Rambam Health Care Campus, Haifa
- Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva
- Rabin Medical Center (IL)
- Corresponding author
- Yahav, Dafna
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12-11
- Volume
- 69
- Issue
- 7
- Pages
- 1091-1098
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2904708694
- Cited by
- 433
- References
- 19
- Citations by year
- 2026: 51 · 2025: 71 · 2024: 47 · 2023: 60 · 2022: 73 · 2021: 52 · 2020: 51 · 2019: 25 · 2018: 2
- FWCI
- 19.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Keywords
- gram-negative bacteremia, antibiotic duration, short-course antibiotic therapy, non-inferiority, Enterobacteriaceae, urinary tract infection, antibiotic stewardship, all-cause mortality, relapse, hospital readmission, functional recovery
- MeSH terms
- Duration of Therapy, Aged, Aged, 80 and over, Anti-Bacterial Agents, Female, Humans, Male, Middle Aged, Bacteremia, Treatment Outcome, Gram-Negative Bacterial Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review